Attached files
| file | filename |
|---|---|
| 8-K - 8-K - CareDx, Inc. | d424619d8k.htm |
Exhibit 99.1
CareDx Reports Second Quarter 2017 Financial Results
Reports 16% AlloMap Revenue Growth
BRISBANE, Calif., August 10, 2017 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the second quarter ended June 30, 2017.
Recent highlights:
| • | Achieved total revenue for the second quarter of 2017 of $12.0 million |
| ○ | AlloMap® revenue was $8.4 million in the quarter, up 16% year-over-year |
| ○ | Olerup® revenue contributed $3.4 million in the second quarter |
| • | Reported US test volume growth of 7% year-over-year and provided the 100,000th AlloMap patient test result |
| • | Signed agreements restructuring and extending the maturity of certain obligations related to CareDx’s acquisition of the Olerup pre-transplant business |
| • | Achieved reimbursement milestones with Palmetto, Noridian and other Medicare Administrative Contractors (MAC) publishing positive AlloSure draft LCDs (Local Coverage Determinations) in May |
“With our core products performing well, we have a great platform in place to grow CareDx’s business in 2018 and beyond. We are excited to be a few months in front of our October AlloSure launch, which provides a transformational business opportunity for us,” said Peter Maag, CareDx President and Chief Executive Officer. “We recently restructured the obligations with certain shareholders, which has increased our financial flexibility ahead of the launch and allows us to continue our drive toward profitability in 2018.”
Second Quarter 2017 Financial Results
Revenue for the three months ended June 30, 2017 was $12.0 million compared with $10.7 million in the second quarter of 2016. Revenue from AlloMap tests for the three months ended June 30, 2017 was $8.4 million compared with $7.2 million in the second quarter of 2016. Olerup revenue in the three months ended June 30, 2017 was $3.4 million.
For the second quarter of 2017, net loss was $4.0 million compared to net loss of $10.5 million in the second quarter of 2016. Basic and diluted net loss per share was $0.19 in the second quarter of 2017, compared to basic and diluted net loss per share of $0.77 in the second quarter of 2016.
For the second quarter of 2017, non-GAAP net loss was $3.6 million compared to non-GAAP net loss of $4.0 million in the second quarter of 2016. Non-GAAP basic and diluted net loss per share was $0.17 in the second quarter of 2017, compared to the non-GAAP basic and diluted net loss per share of $0.29 in the second quarter of 2016.
Net cash used in operating activities in the second quarter of 2017 declined to $3.2 million compared with $6.7 million in the first quarter of 2017. Cash and cash equivalents were $9.1 million as of June 30, 2017.
For additional information regarding non-GAAP financial measures discussed herein, please see “Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
2017 Guidance
For the full year 2017, CareDx expects revenue to be in the range of $46 million to $49 million, excluding any potential AlloSure revenue.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including, but not limited to our anticipated future financial results, including our guidance for full fiscal 2017 revenue, AlloMap test volume growth and the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies. These factors, together with those that are described in our filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed by us with the SEC on April 21, 2017. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Use of Non-GAAP Financial Measures
CareDx has presented certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis in this release, including non-GAAP net loss and non-GAAP basic and diluted net loss per share. We define non-GAAP net loss and per share results as the GAAP net loss and per share results excluding the impacts of stock-based compensation; changes in estimated fair value of warrants, derivative liabilities and contingent consideration; acquisition related impairment charges and amortization of intangible assets, purchase accounting adjustments and related tax effects, costs involved with completing an acquisition; amortization of debt discount; and certain other financing charges. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management, and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly-titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.
Investor Contact
Caroline Corner, Managing Director
Westwicke Partners, LLC
T: +1 415-202-5678
E: caroline.corner@westwicke.com
CareDx, Inc.
Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue: |
||||||||||||||||
| Testing revenue |
$ | 8,420 | $ | 7,249 | $ | 16,322 | $ | 13,704 | ||||||||
| Product revenue |
3,376 | 3,475 | 7,043 | 3,475 | ||||||||||||
| Collaboration and license revenue |
250 | 11 | 265 | 118 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenue |
12,046 | 10,735 | 23,630 | 17,297 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Cost of testing |
3,011 | 2,852 | 6,068 | 5,624 | ||||||||||||
| Cost of product |
2,178 | 3,056 | 4,505 | 3,056 | ||||||||||||
| Research and development |
3,118 | 3,143 | 6,401 | 6,302 | ||||||||||||
| Sales and marketing |
3,270 | 3,356 | 6,492 | 5,093 | ||||||||||||
| General and administrative |
4,132 | 5,393 | 10,634 | 11,070 | ||||||||||||
| Goodwill impairment |
— | — | 1,958 | — | ||||||||||||
| Change in estimated fair value of contingent consideration |
(64 | ) | (97 | ) | (285 | ) | (310 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
15,645 | 17,703 | 35,773 | 30,835 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(3,599 | ) | (6,968 | ) | (12,143 | ) | (13,538 | ) | ||||||||
| Interest expense |
(1,691 | ) | (526 | ) | (2,481 | ) | (783 | ) | ||||||||
| Other expense, net |
(188 | ) | (274 | ) | (874 | ) | (3,200 | ) | ||||||||
| Change in estimated fair value of common stock warrant liability and derivative liability |
1,067 | (3,165 | ) | 5,195 | (3,165 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before income taxes |
(4,411 | ) | (10,933 | ) | (10,303 | ) | (20,686 | ) | ||||||||
| Income tax benefit |
376 | 440 | 659 | 440 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
(4,035 | ) | (10,493 | ) | (9,644 | ) | (20,246 | ) | ||||||||
| Net loss attributable to noncontrolling interest |
(67 | ) | (23 | ) | (114 | ) | (23 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to CareDx, Inc. |
$ | (3,968 | ) | $ | (10,470 | ) | $ | (9,530 | ) | $ | (20,223 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share attributable to CareDx, Inc.: |
||||||||||||||||
| Basic |
$ | (0.19 | ) | $ | (0.77 | ) | $ | (0.45 | ) | $ | (1.58 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
$ | (0.19 | ) | $ | (0.77 | ) | $ | (0.45 | ) | $ | (1.58 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average shares used to compute net loss per share attributable to CareDx, Inc.: |
||||||||||||||||
| Basic |
21,412,480 | 13,568,120 | 21,378,321 | 12,768,913 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
21,412,480 | 13,568,120 | 21,378,321 | 12,768,913 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
CareDx, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
| June 30, 2017 | December 31, 2016 (1) | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 9,104 | $ | 17,258 | ||||
| Accounts receivable |
3,005 | 2,768 | ||||||
| Inventory |
6,343 | 5,461 | ||||||
| Prepaid and other assets |
1,457 | 1,186 | ||||||
|
|
|
|
|
|||||
| Total current assets |
19,909 | 26,673 | ||||||
| Property and equipment, net |
2,528 | 2,931 | ||||||
| Intangible assets, net |
33,743 | 33,124 | ||||||
| Goodwill |
12,005 | 13,839 | ||||||
| Restricted cash |
9,553 | 143 | ||||||
| Other assets |
— | 20 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 77,738 | $ | 76,730 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 3,599 | $ | 3,065 | ||||
| Accrued payroll liabilities |
3,440 | 3,851 | ||||||
| Accrued and other liabilities |
4,960 | 5,320 | ||||||
| Accrued royalties |
304 | 263 | ||||||
| Deferred revenue |
39 | 42 | ||||||
| Deferred purchase consideration |
7,004 | 5,445 | ||||||
| Derivative liability |
1,000 | — | ||||||
| Current debt |
33,890 | 22,846 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
54,236 | 40,832 | ||||||
| Deferred rent, net of current portion |
1,113 | 1,301 | ||||||
| Deferred revenue, net of current portion |
750 | 759 | ||||||
| Deferred tax liability |
5,894 | 6,057 | ||||||
| Long-term debt, net of current portion |
— | 1,098 | ||||||
| Contingent consideration |
207 | 492 | ||||||
| Common stock warrant liability |
2,203 | 5,208 | ||||||
| Other liabilities |
1,349 | 1,222 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
65,752 | 56,969 | ||||||
| Stockholders’ equity: |
||||||||
| Common stock |
21 | 21 | ||||||
| Additional paid-in capital |
236,617 | 235,673 | ||||||
| Accumulated other comprehensive loss |
(2,724 | ) | (3,659 | ) | ||||
| Accumulated deficit |
(222,083 | ) | (212,553 | ) | ||||
|
|
|
|
|
|||||
| Total CareDx, Inc. stockholders’ equity |
11,831 | 19,482 | ||||||
| Noncontrolling interest |
155 | 279 | ||||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
11,986 | 19,761 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 77,738 | $ | 76,730 | ||||
|
|
|
|
|
|||||
| (1) | The condensed balance sheets at December 31, 2016 have been derived from audited financial statements. |
CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands, except share and per share data)
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Cost of testing reconciliation: |
||||||||||||||||
| GAAP cost of testing |
$ | 3,011 | $ | 2,852 | $ | 6,068 | $ | 5,624 | ||||||||
| Stock-based compensation expense |
(64 | ) | (38 | ) | (119 | ) | (66 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP cost of testing |
$ | 2,947 | $ | 2,814 | $ | 5,949 | $ | 5,558 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of product reconciliation: |
||||||||||||||||
| GAAP cost of product |
$ | 2,178 | $ | 3,056 | $ | 4,505 | $ | 3,056 | ||||||||
| Acquisition related-amortization of purchased intangibles |
(353 | ) | (303 | ) | (710 | ) | (303 | ) | ||||||||
| Acquisition related-amortization of inventory valuation adjustment |
(138 | ) | (1,225 | ) | (170 | ) | (1,225 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP cost of product |
$ | 1,687 | $ | 1,528 | $ | 3,625 | $ | 1,528 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Research and development expenses reconciliation: |
||||||||||||||||
| GAAP research and development expenses |
$ | 3,118 | $ | 3,143 | $ | 6,401 | $ | 6,302 | ||||||||
| Stock-based compensation expense |
(111 | ) | (100 | ) | (175 | ) | (213 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP research and development expenses |
$ | 3,007 | $ | 3,043 | $ | 6,226 | $ | 6,089 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Sales and marketing expenses reconciliation: |
||||||||||||||||
| GAAP sales and marketing expenses |
$ | 3,270 | $ | 3,356 | $ | 6,492 | $ | 5,093 | ||||||||
| Acquisition related-amortization of purchased intangibles |
(234 | ) | (213 | ) | (465 | ) | (213 | ) | ||||||||
| Stock-based compensation expense |
(57 | ) | (43 | ) | (95 | ) | (71 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP sales and marketing expenses |
$ | 2,979 | $ | 3,100 | $ | 5,932 | $ | 4,809 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| General and administrative expenses reconciliation: |
||||||||||||||||
| GAAP general and administrative expenses |
$ | 4,132 | $ | 5,393 | $ | 10,634 | $ | 11,070 | ||||||||
| Acquisition related fees and expenses |
— | (1,581 | ) | — | (3,840 | ) | ||||||||||
| Stock-based compensation expense |
(263 | ) | (186 | ) | (497 | ) | (463 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP general and administrative expenses |
$ | 3,869 | $ | 3,626 | $ | 10,137 | $ | 6,767 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Goodwill impairment reconciliation: |
||||||||||||||||
| GAAP goodwill impairment |
$ | — | $ | — | $ | 1,958 | $ | — | ||||||||
| Goodwill impairment |
— | — | (1,958 | ) | — | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP goodwill impairment |
$ | — | $ | — | $ | — | $ | — | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Change in estimated fair value of contingent consideration reconciliation: |
||||||||||||||||
| GAAP change in estimated fair value of contingent consideration |
$ | (64 | ) | $ | (97 | ) | $ | (285 | ) | $ | (310 | ) | ||||
| Change in estimated fair value of contingent consideration |
64 | 97 | 285 | 310 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP change in estimated fair value of contingent consideration |
$ | — | $ | — | $ | — | $ | — | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Interest expense reconciliation: |
||||||||||||||||
| GAAP interest expense |
$ | (1,691 | ) | $ | (526 | ) | $ | (2,481 | ) | $ | (783 | ) | ||||
| Amortization of debt discount |
606 | 43 | 717 | 84 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP interest expense |
$ | (1,085 | ) | $ | (483 | ) | $ | (1,764 | ) | $ | (699 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Other expense, net reconciliation: |
||||||||||||||||
| GAAP other expense, net |
$ | (188 | ) | $ | (274 | ) | $ | (874 | ) | $ | (3,200 | ) | ||||
| Debt financing related fees and expenses |
(125 | ) | 60 | 309 | 2,939 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP other expense, net |
$ | (313 | ) | $ | (214 | ) | $ | (565 | ) | $ | (261 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Change in estimated fair value of common stock warrant liability and derivative liability reconciliation: |
||||||||||||||||
| GAAP change in estimated fair value of common stock warrant liability and derivative liability |
$ | 1,067 | $ | (3,165 | ) | $ | 5,195 | $ | (3,165 | ) | ||||||
| Change in estimated fair value of common stock warrant liability and derivative liability reconciliation: |
(1,067 | ) | 3,165 | (5,195 | ) | 3,165 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP change in estimated fair value of common stock warrant liability and derivative liability |
$ | — | $ | — | $ | — | $ | — | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income tax benefit reconciliation: |
||||||||||||||||
| GAAP income tax benefit |
$ | 376 | $ | 440 | $ | 659 | $ | 440 | ||||||||
| Tax effect related to amortization of purchased intangibles |
(181 | ) | (427 | ) | (336 | ) | (427 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP income tax benefit |
$ | 195 | $ | 13 | $ | 323 | $ | 13 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss reconciliation: |
||||||||||||||||
| GAAP net loss attributable to CareDx, Inc. |
$ | (3,968 | ) | $ | (10,470 | ) | $ | (9,530 | ) | $ | (20,223 | ) | ||||
| Acquisition related-amortization of purchased intangibles |
587 | 516 | 1,175 | 516 | ||||||||||||
| Acquisition related-amortization of inventory valuation adjustment |
138 | 1,225 | 170 | 1,225 | ||||||||||||
| Tax effect related to amortization of purchased intangibles |
(181 | ) | (427 | ) | (336 | ) | (427 | ) | ||||||||
| Acquisition related fees and expenses |
— | 1,581 | — | 3,840 | ||||||||||||
| Debt financing related fees and expenses |
(125 | ) | 60 | 309 | 2,939 | |||||||||||
| Amortization of debt discount |
606 | 43 | 717 | 84 | ||||||||||||
| Stock-based compensation expenses |
495 | 367 | 886 | 813 | ||||||||||||
| Goodwill impairment |
— | — | 1,958 | — | ||||||||||||
| Change in estimated fair value of contingent consideration |
(64 | ) | (97 | ) | (285 | ) | (310 | ) | ||||||||
| Change in estimated fair value of common stock warrant liability and derivative liability |
(1,067 | ) | 3,165 | (5,195 | ) | 3,165 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP net loss |
$ | (3,579 | ) | $ | (4,037 | ) | $ | (10,131 | ) | $ | (8,378 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic and diluted net loss per share reconciliation: |
||||||||||||||||
| GAAP basic and diluted net loss per share attributable to CareDx |
$ | (0.19 | ) | $ | (0.77 | ) | $ | — | $ | (1.58 | ) | |||||
| Acquisition related-amortization of purchased intangibles |
0.03 | 0.04 | 0.05 | 0.04 | ||||||||||||
| Acquisition related-amortization of inventory valuation adjustment |
0.01 | 0.09 | 0.01 | 0.10 | ||||||||||||
| Tax effect related to amortization purchased intangibles |
(0.01 | ) | (0.03 | ) | (0.02 | ) | (0.03 | ) | ||||||||
| Acquisition related fees and expenses |
— | 0.12 | — | 0.30 | ||||||||||||
| Debt financing related fees and expenses |
(0.01 | ) | 0.00 | 0.01 | 0.23 | |||||||||||
| Amortization of debt discount |
0.03 | 0.00 | 0.03 | 0.01 | ||||||||||||
| Stock-based compensation expenses |
0.02 | 0.03 | 0.04 | 0.03 | ||||||||||||
| Goodwill impairment |
— | — | 0.09 | — | ||||||||||||
| Change in estimated fair value of contingent consideration |
(0.00 | ) | (0.01 | ) | (0.01 | ) | (0.02 | ) | ||||||||
| Change in estimated fair value of common stock warrant liability and derivative liability |
(0.05 | ) | 0.23 | (0.24 | ) | 0.25 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP basic and diluted net loss per share attributable to CareDx |
$ | (0.17 | ) | $ | (0.29 | ) | $ | (0.03 | ) | $ | (0.69 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP adjustment summary: |
||||||||||||||||
| Cost of testing |
$ | 64 | $ | 38 | $ | 119 | $ | 66 | ||||||||
| Cost of product |
491 | 1,528 | 880 | 1,528 | ||||||||||||
| Research and development |
111 | 100 | 175 | 213 | ||||||||||||
| Sales and marketing |
291 | 256 | 560 | 284 | ||||||||||||
| General and administrative |
263 | 1,767 | 497 | 4,303 | ||||||||||||
| Goodwill impairment |
— | — | 1,958 | — | ||||||||||||
| Change in estimated fair value of contingent consideration |
(64 | ) | (97 | ) | (285 | ) | (310 | ) | ||||||||
| Interest expense |
606 | 43 | 717 | 84 | ||||||||||||
| Other expense, net |
(125 | ) | 60 | 309 | 2,939 | |||||||||||
| Change in estimated fair value of common stock warrant liability and derivative liability |
(1,067 | ) | 3,165 | (5,195 | ) | 3,165 | ||||||||||
| Tax effect related to amortization of purchased intangibles |
(181 | ) | (427 | ) | (336 | ) | (427 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Non-GAAP adjustment summary: |
$ | 389 | $ | 6,433 | $ | (601 | ) | $ | 11,845 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||